Classic and Overlap Chronic Graft-versus-Host Disease (cGVHD) Is Associated with Superior Outcome after Extracorporeal Photopheresis (ECP) Madan H. Jagasia,

Slides:

Advertisements

Similar presentations

Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic.

Advertisements

Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

Nishitha M. Reddy, Olalekan Oluwole, John P. Greer, Brian G

Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease Melanie N. Stauber,

Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular.

Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin.

Validation of National Institutes of Health Global Scoring System for Chronic Graft- Versus-Host Disease (GVHD) According to Overall and GVHD-Specific.

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab Marc Schnitzler, Jens Hasskarl,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome Philippe Armand,

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies

Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated.

Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation Bipin N. Savani, Theresa Donohue,

Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life

Clinical Benefit of Response in Chronic Graft-versus-Host Disease

Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (Prochymal™) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host.

Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma Robert Chen, Joycelynne.

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review

Dysglycemia Following Glucocorticoid Therapy for Acute Graft-versus-Host Disease Adversely Affects Transplantation Outcomes Joseph Pidala, Jongphil Kim,

Geographic Distance Is Not Associated with Inferior Outcome When Using Long-Term Transplant Clinic Strategy Brittany Knick Ragon, Carey Clifton, Heidi.

Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia George L. Chen, Hong Liu,

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan.

Betty K. Hamilton, Lisa Rybicki, Sally Arai, Mukta Arora, Corey S

Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease Daniel R. Couriel, Rima Saliba, Marcos.

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High- Risk Acute Lymphoblastic Leukemia Samer A. Srour, Denái R. Milton,

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma Eric Smith, Sean M. Devlin, Satyajit.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Sustained Suppression of Involved Free Light Chain Predicts Long Term Outcomes in Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation:

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts Boglarka.

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft- versus-Host Disease: A Scoping Review of the Evidence Mina Rizk, Madeline.

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos

High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic.

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell.

Biology of Blood and Marrow Transplantation

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial

Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.

Incidence and Outcome of Chronic Graft-versus-Host Disease Using National Institutes of Health Consensus Criteria Madan Jagasia, Jennifer Giglia, Wichai.

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Biology of Blood and Marrow Transplantation

TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT: Lower TNFR1 Levels Correlate with Better Outcomes Sung W. Choi,

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Daniel Couriel, Chitra Hosing, Rima Saliba, Elizabeth J

Extracorporeal Photopheresis versus Anticytokine Therapy as a Second-Line Treatment for Steroid-Refractory Acute GVHD: A Multicenter Comparative Analysis

Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease Joseph Pidala, Jongphil Kim, Teresa Field, Ali McBride, Mohamed Kharfan-Dabaja,

Presentation transcript:

Classic and Overlap Chronic Graft-versus-Host Disease (cGVHD) Is Associated with Superior Outcome after Extracorporeal Photopheresis (ECP) Madan H. Jagasia, Bipin N. Savani, George Stricklin, Brian Engelhardt, Adetola Kassim, Sheri Dixon, Heidi Chen, Wichai Chinratanalab, Stacey Goodman, John P. Greer, Friedrich Schuening Biology of Blood and Marrow Transplantation Volume 15, Issue 10, Pages 1288-1295 (October 2009) DOI: 10.1016/j.bbmt.2009.06.007 Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Flow diagram summarizing disposition of patients during the period of study analyses. The dark gray boxes with solid lines show the response of GVHD to ECP (CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease). The light gray boxes with the dashed lines show the GVHD subtype (CA, classic acute; RA, recurrent acute; OV, overlap chronic; CC, classic chronic).∗Reflects 1 missing patient. Biology of Blood and Marrow Transplantation 2009 15, 1288-1295DOI: (10.1016/j.bbmt.2009.06.007) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 OS (from initiation of ECP) stratified by GVHD type. (A) Patients with aGVHD (persistent acute, recurrent acute, delayed acute) overlap cGVHD, and classic cGVHD had significantly different OS (P=.001). (B) aGVHD versus overlap plus classic cGVHD. (C) Any aGVHD (classic, recurrent, overlap) versus classic cGVHD. Biology of Blood and Marrow Transplantation 2009 15, 1288-1295DOI: (10.1016/j.bbmt.2009.06.007) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 OS (from initiation of ECP) stratified by best response to ECP. The overall survival of patients with response (CR or PR) (median survival, not reached), stabilization of GVHD (median survival, 217 days) or progression (median survival, 39 days) was significantly different (P < .0001). CR, complete response; PR, partial response. Biology of Blood and Marrow Transplantation 2009 15, 1288-1295DOI: (10.1016/j.bbmt.2009.06.007) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 NRM with death from relapse as a competing risk. (A) NRM of patients with aGVHD (classic acute, recurrent acute) compared with cGVHD (overlap plus classic chronic) (P < .0001). (B) NRM of patients with any aGVHD (classic acute, recurrent, overlap) compared with classic cGVHD (P=.007). Biology of Blood and Marrow Transplantation 2009 15, 1288-1295DOI: (10.1016/j.bbmt.2009.06.007) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions